INDICATIONS
Built for breakthroughs. Engineered to scale.
Driven by scientific inquiry and built with intentional rigor, this is where bold conceptual advances converge with disciplined, methodical execution.
LEAD INDICATION
Spinal cord injury
~300,000 patients living with spinal cord injury
NO CURRENT TREATMENT MITIGATES FUNCTIONAL LOSS OR DRIVES REGENERATION.
The spinal cord does not regenerate on its own. A glial scar forms at the site of injury, physically and chemically blocking axons from reconnecting across the lesion, such that the disconnection sustained at the moment of injury becomes permanent.
Engineered tissues are designed to bridge that scar directly: a pre-formed, living pathway that gives severed axons a structure to grow along rather than a barrier to overcome.
THE EVIDENCE
Demonstrated survival, structural integration, and long-distance axon growth following transplantation.
Our research in engineered tissue for spinal cord injury has demonstrated that lab made engineered tissue constructs can survive transplantation, integrate with host tissue, and support long-distance axon growth in spinal cord injury models.
The next challenge is replacing variable, labor-intensive production with standardized manufacturing capable of supporting clinical translation.
ONE PLATFORM, MULTIPLE INDICATIONS.